Enhanced platelet inhibition by adjunctive cilostazol to dual antiplatelet therapy after drug-eluting stent implantation for complex lesions

Young-Hoon Jeong; Yongwhi Park; In-Suk Kim; Seong-Eun Yun; Min-Kyung Kang; Seok-Jae Hwang; Choong Hwan Kwak; Jin-Yong Hwang

doi:10.1160/TH10-04-0239

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 2010; 104(06): 1286-1289
DOI: 10.1160/TH10-04-0239

Letters to the Editor

Schattauer GmbH

Enhanced platelet inhibition by adjunctive cilostazol to dual antiplatelet therapy after drug-eluting stent implantation for complex lesions

Young-Hoon Jeong

¹Division of Cardiology, Department of Internal Medicine, Gyeongsang National University Hospital, Jinju, Korea

,

Yongwhi Park

¹Division of Cardiology, Department of Internal Medicine, Gyeongsang National University Hospital, Jinju, Korea

,

In-Suk Kim

²Department of Laboratory Medicine, Gyeongsang National University Hospital, Jinju, Korea

,

Seong-Eun Yun

¹Division of Cardiology, Department of Internal Medicine, Gyeongsang National University Hospital, Jinju, Korea

,

Min-Kyung Kang

¹Division of Cardiology, Department of Internal Medicine, Gyeongsang National University Hospital, Jinju, Korea

,

Seok-Jae Hwang

¹Division of Cardiology, Department of Internal Medicine, Gyeongsang National University Hospital, Jinju, Korea

,

Choong Hwan Kwak

¹Division of Cardiology, Department of Internal Medicine, Gyeongsang National University Hospital, Jinju, Korea

,

Jin-Yong Hwang

¹Division of Cardiology, Department of Internal Medicine, Gyeongsang National University Hospital, Jinju, Korea

› Author Affiliations

Abstract

Full Text

References

References
1 Grines CL. Off-label use of drug-eluting stents putting it in perspective. J Am Coll Cardiol 2008; 51: 615-617.
2 Wallentin L. P2Y₁₂ inhibitors: differences in properties and mechanisms of action and potential consequences for clinical use. Eur Heart J 2009; 30: 1964-1977.
3 Cook S, Windecker S. Early stent thrombosis: past, present, and future. Circulation 2009; 119: 657-659.
4 Windecker S, Meier B. Late coronary stent thrombosis. Circulation 2007; 116: 1952-1965.
5 Ferreiro JL, Angiolillo DJ. Clopidogrel response variability: current status and future directions. Thromb Haemost 2009; 102: 7-14.
6 Hattori Y, Suzuki K, Tomizawa A. et al. Cilostazol inhibits cytokine-induced nuclear factor-kappaB activation via AMP-activated protein kinase activation in vascular endothelial cells. Cardiovasc Res 2009; 81: 133-139.
7 Lee SW, Park SW, Yun SC. et al. Triple antiplatelet therapy reduces ischemic events after drug-eluting stent implantation: Drug-Eluting stenting followed by Cilostazol treatment REduces Adverse Serious cardiac Events (DECREASE registry). Am Heart J 2010; 159: 284-291.e1.
8 Lee BK, Lee SW, Park SW. et al. Effects of triple anti-platelet therapy with aspirin, clopidogrel and cilostazol on platelet aggregation and P-selectin expression in patients undergoing coronary artery stent implantation. Am J Cardiol 2007; 100: 610-614.
9 Hayashi H, Sudo T. Effects of the cAMP-elevating agents cilostamide, cilostazol and forskolin on the phosphorylation of Akt and GSK-3beta in platelets. Thromb Haemost 2009; 102: 327-335.
10 Kim IS, Jeong YH, Kang MK. et al. Correlation of high post-clopidogrel platelet reactivity assessed by light transmittance aggregometry and the VerifyNow P2Y₁₂ assay. J Thromb Thrombolys. 2010 ((please complete reference)).
11 Von Beckerath N, Kastrati A, Wieczorek A. et al. A double-blind, randomized study on platelet aggregation in patients treated with a daily dose of 150 or 75 mg of clopidogrel for 30 days. Eur Heart J 2007; 28: 1814-1819.
12 Geisler T, Zürn C, Simonenko R. et al. Early but not late stent thrombosis is influenced by residual platelet aggregation in patients undergoing coronary interventions. Eur Heart J 2010; 31: 59-66.
13 Sibbing D, Morath T, Braun S. et al. Clopidogrel response status assessed with Multiplate point-of-care analysis and the incidence and timing of stent thrombosis over six months following coronary stenting. Thromb Haemost 2010; 103: 151-159.
14 Wiviott SD, Braunwald E, McCabe CH. et al. TRITON-TIMI 38 Investigators.. Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the TRITON-TIMI 38 trial: a subanalysis of a randomised trial. Lancet 2008; 371: 1353-1363.
15 Lee SW, Park SW, Kim YH. et al. Drug-eluting stenting followed by cilostazol treatment reduces late restenosis in patients with diabetes mellitus the DECLARE-DIABETES Trial (A Randomized Comparison of Triple Antiplatelet Therapy with Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation in Diabetic Patients). J Am Coll Cardiol 2008; 51: 1181-1187.
16 Ota H, Eto M, Ako J. et al. Sirolimus and everolimus induce endothelial cellular senescence via sirtuin 1 down-regulation: therapeutic implication of cilostazol after drug-eluting stent implantation. J Am Coll Cardiol 2009; 53: 2298-2305.
17 Cuisset T, Cayla G, Frere C. et al. Predictive value of post-treatment platelet reactivity for occurrence of post-discharge bleeding after non-ST elevation acute coronary syndrome. Shifting from antiplatelet resistance to bleeding risk assessment? EuroIntervention 2009; 5: 325-329.
18 Sibbing D, Schulz S, Braun S. et al. Antiplatelet effects of clopidogrel and bleeding in patients undergoing coronary stent placement. J Thromb Haemost 2010; 8: 250-256.
19 Hobson A, Curzen N. Improving outcomes with antiplatelet therapies in percutaneous coronary intervention and stenting. Thromb Haemost 2009; 101: 23-30.